Cardiomyopathy, Myocarditis, Ischemic Heart Disease Clinical Trial
— MyomappingOfficial title:
Novel Magnetic Resonance Imaging Techniques for Quantitative Cardiac Parametric Mapping
The overall goal of this project is to evaluate the clinical potential of fast quantitative myocardial tissue characterization using recently emerged Cardiac Magnetic Resonance Imaging (CMR) techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases, such as ischemic heart disease, cardiomyopathies, and myocarditis.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | October 15, 2024 |
Est. primary completion date | October 15, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Subject must be 18-90 years of age. - Subject must be previously diagnosed with or suspected to have one of the following conditions. - Myocardial ischemia or infarction (group 1) - Hypertrophic cardiomyopathy (group 2) - Infiltrative cardiomyopathy (group 3) - Myocarditis (group 4) - Subject must have been referred for a clinically indicated CMR. Exclusion Criteria: - Subject has any implanted device or condition in which an MR scan would be contraindicated. - Subject has an acute psychiatric disorder or is cognitively impaired. - Subject is using or is dependent on substances of abuse. - Subject is unwilling to comply with the requirements of the protocol. - Subject has previously entered this study. - Subject has an allergy against MRI contrast agents. - Subject is in acute unstable condition. |
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical value of fast T1, T2, and T2* mapping of the left ventricle for the assessment of necrosis/scar, edema, and possible intramyocardial hemorrhage in patients with heart disease. | 2 years |